SHL Telemedicine Ltd

Latest Results (07.02.2026):

SHL Telemedicine Ltd — Half-Year (H1) 2024: SHL reported HY2024 revenues of USD 27.9m (down ~2% on a constant-currency basis versus HY2023), an adjusted EBITDA of USD 0.5m (up from USD 0.3m), and a net loss of USD 3.9m (worse than HY2023’s net loss of ~USD 2.2m). Cash and short-term investments were USD 20.3m at June 30, 2024. Management highlights operational improvement in Israel and Germany, continued investment in U.S. direct-to-consumer (D2C) initiatives, and positive preliminary clinical signals from a Mayo Clinic study.

Top-line and regional revenue mix

Total HY2024 revenues were USD 27.9m. By geography: Israel USD 20.9m (flat vs prior period), Germany USD 6.6m (slightly down), and Rest of World USD 0.4m (decline). HY2024 revenues were modestly lower versus HY2023 on both reported and constant-currency bases.

Profitability — adjusted and GAAP measures

Adjusted EBITDA (constant currency) improved to USD 0.5m (HY2023: USD 0.3m), driven by operational improvements. Unadjusted EBITDA was negative USD 0.2m. Adjusted EBIT remained negative at USD (3.2)m.

Net loss and financial items

Net loss for HY2024 was USD 3.9m compared with a loss of about USD 2.2m in HY2023. Financial income, net fell to USD 0.5m from USD 3.0m, largely due to a non‑cash investors‑options income recognized in HY2023 and FX effects.

Cash and liquidity

Cash and short-term investments stood at USD 20.3m as of June 30, 2024, down from USD 26.2m at year-end 2023.

Operational highlights and investments

Adjusted EBITDA in Israel rose ~4%; Germany reduced operational losses by approximately USD 1.0m; SHL increased U.S. D2C investments by roughly USD 0.7m as it explores expansion in that market.

Management and clinical update

New leadership was appointed (including CEO David Arnon and chairman Dr. Itamar Offer). Management emphasises cost control, platform/ service expansion and identifying growth drivers. Preliminary Mayo Clinic randomized study results reportedly show a favorable trend toward reduced ER visits and re‑hospitalizations for users of SHL devices.

Outlook and investor communications

Management is focused on growth initiatives across territories and further cost efficiencies. The company hosted a HY2024 conference call and has posted the full Half‑Year report and presentation on its investor pages and SEC filings for detailed financial disclosures.